@EASLnews my 4 year old has started wearing “his” #ILC2022 badge regularly. Might see an application from a pediatric corresponding member coming your way!

@flyLAXairport bound , barely 24 h after returning from #ILC2022 I need a better travel planner!

The presenters @FTibertLarsen @Lauraalmale @HejnKamilla signing off from the #ILC2022!

Thanks to the #EASL for facilitating an inspiring week of #LiverTwitter science. See you next year 👋

@EASLnews @ATLAS_SDU @GenomicsUnit

Thank you @EASLnews for putting together a fantastic #ILC2022 Even my dislike for @ExCeLLondon didn’t prevent me from enjoying all the F2F interactions and great content. Will definitely plan to attend #ILC2023 in Vienna. See many of you at @AASLDtweets #LiverMtg22 in DC

@HeathrowAirport terrible delays today so please give yourself at least 4 hours. It took me 3 hours to check a bag and go through security #ILC2022

Kamilla exchanging insights with one of countless visitors at her poster. Another great day at #ILC2022. @ATLAS_SDU @DDA_Denmark

@EASLnews @EASLedu great discussion around ##HCC IO beyond progression, pseudoprogresssion and the all important issue of sequencing @ma5RN @massimoiava @LorenzaRimassa @AndrewMMoon #ILC2022

@EASLedu @EASLnews improvement in MRE and #VCTE at both 100 and 80 mg doses of #resmetirom limitations include low fibrosis burden in participants. AE included diarrhea and nausea mostly in the first 12 weeks. #ILC2022

@EASLedu @EASLnews both 80 and 100 mg doses of #resmetirom in MAESTRO-NAFLD1 achieved secondary endpoints #ILC2022

@EASLedu @EASLnews Dr. Steve Harrison @Pinnacle_TX presents data for ph3 #resmetirom MAESTRO-NAFLD1 study. Design shown below #ILC2022

@EASLedu prof. Man Fung Yuen. B-CLEAR study of #bepirovirsen sc in both nuc naive and experienced #HBV patients. HBsAg loss mostly in those w/ low sAg titers at baseline and those on nucs. Flares associated with HBsAg decline ?immune restauration #ILC2022

@EASLnews @EASLedu @DrLoomba during Q&A feels patients are improving during trial but histological tools we have are not capturing this over short period of time. I strongly agree with that. #ILC2022

@EASLedu @EASLedu @DrLoomba #GLP-1 #semaglutide ph2 trial of 2.4 mg sc qwk vs. placebo in #NASH cirrhosis doesn’t meet 1ry endpoint. Very interesting is how different histological asesssments (AI vs “traditional”) yield different results #ILC2022

@EASLedu one thing I learned from the vigorous #HCC tumor board discussion with @riadsalemIR @ma5RN @bruixj @massimoiava @allaire_manon @NaultJc is that where you live around the world plays a major role in what treatments you are offered. #ILC2022

@EASLnews @EASLnews great to see @GlobalLiver represented at #ILC2022
Proud to represent @OHIOLIVER along with many colleagues and stakeholders @DCPatient @AlkhouriNaim @guts44 @scottasuckow @SDLiver

@EASLedu @EASLnews @Ant_Martinez26 HCV DAAs very rarely associated with opioid adverse events. Time to prioritize HCV treatment for #PWID #ILC2022

@EASLnews @EASLedu #ILC2022 highlights for me tomorrow include screening and surveillance for #HCC, disease heterogeneity in #NAFLD and #baveno7 updates

@EASLedu @EASLedu @HeinerWedemeyer #bulevirtide (BLV) @ 2mg sc QD x 48 wks leads to 45% response (undect. RNA or 2 log drop with nl ALT). LSM ⬇️. ⬆️bile salts due to NTCP blocade. No SAEs but slightly more itching. Planned for 144 wks. @US_FDA currently vetting. #ILC2022

@EASLedu the quest for an #HCC bio marker for early stage/curable disease continues. Adding L3-AFP and DCP doesn’t seem to do the trick #ILC2022

@EASLedu fascinating talk by Dr. Zimmer about diff. between immune checkpoint blockade (ICB) hepatitis & type 1 AIH. More pericentral disease in ICB with dense CV infiltration w CD8+ T cells & mTOR pathway activated macrophages.
#everolimus for ICB-hepatitis?
#ILC2022

@EASLedu @IsraelsenMads results of 18 mos. #Rifaximin vs. placebo RCT evaluating fibrosis in non sober alc hepatitis.
✅ 7 years to complete
✅ 21% drop out
✅ no effect on fibrosis reduction
✅reduction in fibrosis progression
✅ seems safe. No c diff

More Q Than A
#ILC2022

@EASLnews at the @Hep_Alliance pledge wall. No #HCV elimination without #harmreduction #ILC2022

@EASLedu I’m struck by the therapeutic optimism conveyed in the PGC about #HCV being mostly a thing of the past. If you want an immediate and potent counterpoint, come to Ohio/Kentucky/Tennessee/West Virginia: the epicenter of the US #opioidepidemic #harmreduction #ILC2022

@EASLnews things are happening at the #ILC2022 community hub!

@EASLedu highlights of day 2 of #ILC2022 for me will include sessions on personalised medicine options in #HCC and ##NAFLD. Kudos to @EASLnews for including a session on digitalised medicine: harnessing social media, AI to optimize care @MajaThiele @DrLoomba @Dr_Vijay_Shah

Great time networking and connecting with friends not seen in 2+ years at the annual @EASLedu @CLDFoundation reception with spectacular views of London from atop the cheese grater #ILC2022

@EASLedu Dr. Gramantieri biomarkers for #HCC
🥵 AFP sens 60% spec 80% upon surveillance
🫢 #ctDNA multi target HCC blood test (mt-HBT) sens 88% spec 87% for early stage dz
😬 circulating Tumor cells (CTC) plus #ctDNA sens and spec in 90% in detection of residual dz
#ILC2022

@EASLedu @elizabeth_verna excellent point about #sarcopenia “we know it increases wait list mortality but what can be done about it?” #ILC2022

medcalculators | MELD 3.0

⁦@EASLedu⁩ @EASLnews⁩ link to MELD 3.0 below. This is currently under consideration for replacement of previous version as early as next weekand may address issues with albumin, CKD and sex disparities #ilc2022 https://medcalculators.stanford.edu/meld

@EASLedu @elizabeth_verna eGFR estimate equations instead of creatinine may help address disparities. Equations that include sex and cystatin c may be better.
Edit. Note: not a big fan of cystatin C
#ILC2022